(Q36111541)

12 August 2017

Thyroid cancer: molecular aspects and new therapeutic strategies (English)

1 reference

12 August 2017

1 reference

Enrique Grande

1

1 reference

12 August 2017

Juan José Díez

series ordinal

2

1 reference

12 August 2017

Carles Zafon

series ordinal

3

1 reference

12 August 2017

Jaume Capdevila

series ordinal

4

1 reference

12 August 2017

12 July 2012

1 reference

Journal of Thyroid Research

12 August 2017

1 reference

12 August 2017

2012

1 reference

12 August 2017

847108

1 reference

Creative Commons Attribution 3.0 Unported

12 August 2017

start time

1 January 2012

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Approach to the patient with advanced differentiated thyroid cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Thyroid cancer: emerging role for targeted therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

RET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpoint.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

The mTOR protein as a target in thyroid cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Anaplastic thyroid carcinoma: A comprehensive review of current and future therapeutic options

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Targeting RET receptor tyrosine kinase activation in cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Multikinase inhibitors in thyroid cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Medullary thyroid cancer: molecular biology and novel molecular therapies

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Phase II trial of sorafenib in metastatic thyroid cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Motesanib diphosphate in progressive differentiated thyroid cancer.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Phase II trial of sorafenib in advanced thyroid cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Pathogenetic mechanisms in thyroid follicular-cell neoplasia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Neutralizing vascular endothelial growth factor activity inhibits thyroid cancer growth in vivo

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3403487

Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression.

2 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Chemotherapy with doxorubicin in progressive medullary and thyroid carcinoma of the follicular epithelium.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Sorafenib in metastatic thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Genetic alterations in the RAS/RAF/mitogen-activated protein kinase and phosphatidylinositol 3-kinase/Akt signaling pathways in the follicular variant of papillary thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F847108

Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22848860

12 December 2020

inferred from PubMed ID database lookup

Medullary thyroid carcinoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22848860

12 December 2020

inferred from PubMed ID database lookup

Treatment of advanced differentiated thyroid carcinoma with high activity radioiodine therapy

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22848860

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1155/2012/847108

1 reference

release_ew5z2lopezhljioxkzs6ozne5i

12 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ew5z2lopezhljioxkzs6ozne5i

24 November 2022

mapped directly with Wikidata item

1 reference

12 August 2017

1 reference